Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.49 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82269 | 0.88 | PTGDR2 (0.61) | CCR5SLC6A4PTPN1USP2LMNA | |
| SCHEMBL29690396 | 0.88 | PTGDR2 (0.61) | CCR5SLC6A4PTPN1USP2LMNA | |
| SCHEMBL12953423 | 0.86 | MAOB (0.49) | CCR5LMNAMAOBMAOA | |
| SCHEMBL30679658 | 0.85 | CCR5 (0.59) | CCR5SLC6A4 | |
| SCHEMBL23017937 | 0.84 | CCR5 (0.50) | CCR5SLC6A4PTPN1USP2LMNA | |
| SCHEMBL865350 | 0.83 | MAOA (0.58) | PTPN1CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL13956364 | 0.83 | ERN1 (0.52) | LMNACCNB2CDK1CDK4CCNB1 | |
| SCHEMBL13580973 | 0.82 | ALDH1A1 (0.46) | SLC6A4HTTPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31001958 | 0.82 | HDAC8 (0.54) | CCR5LMNAMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL15056730 | 0.82 | CCR5 (0.48) | CCR5SLC6A4PTPN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008057948-A2 | PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-0773930-B1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LTD (GB) | 2000-10-11 | — | — | EP | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | CCR5 4534/4885SLC6A4 3345/4885PTPN1 4189/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | CCR5 4534/4885SLC6A4 3345/4885PTPN1 4189/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | CCR5 1774/4885SLC6A4 3627/4885PTPN1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.